Drug Trial Radar · NCT05195632
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
63
Actual
Start
Jun 2, 2022
Primary completion
May 27, 2024
Study completion Dec 14, 2026
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either previously untreated or have had one line of prior therapy in metastatic setting.
Conditions
- Non-Small Cell Lung Cancer
Interventions
EncorafenibDrug
Hard capsule
BinimetinibDrug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead-In (SLI) Part: Incidence of Dose-limiting toxicities (DLTs)Time frame: Cycle 1; Each cycle is 28 days
- Pivotal Part: Confirmed objective response rate (cORR)Time frame: Cycle 1 Day 1 through safety follow-up visit (30 days after end of treatment (EOT) visit or 7 days after EOT visit/last dose if EOT not performed), approximately up to 18 months. Each cycle is 28 days.
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Chest Hospital, Capital Medical University
Beijing, China
Peking University First Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Xiangya Hospital Central South University
Changsha, China
Sichuan Cancer Hospital
Chengdu, China
Chongqing University Cancer Hospital
Chongqing, China
The Second Hospital of Dalian University
Dalian, China
Fujian Medical University Union Hospital
Fuzhou, China
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)
Fuzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Hainan General Hospital
Haikou, China
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shandong Cancer Hospital
Jinan, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
Linyi Cancer Hospital
Linyi, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, China
Liaoning Cancer Hospital & Institute
Shenyang, China
The First Hospital of China Medical University
Shenyang, China
Peking University Shenzhen Hospital
Shenzhen, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Union Hospital Tongji medical college Huazhong University of Science and Technology
Wuhan, China
The Northern Jiangsu People's Hospital
Yangzhou, China
Yantai Yuhuangding Hospital
Yantai, China
Henan Cancer Hospital
Zhengzhou, China
Taipei Veterans General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.